WCN'26: HIT! High Impact Clinical Trials 3 - In IgA Nephropathy

Recorded On: 03/29/2026

HIT! High Impact Clinical Trials 3 - In IgA Nephropathy

Key:

Complete
Failed
Available
Locked
Efficacy and Safety Results of Atrasentan in Patients With IgA Nephropathy on Sodium‚ äìglucose Co-transporter 2 Inhibitors: Phase II, Randomized, Placebo-controlled, Crossover Trial (Assist)
Open to view video.
Open to view video.
You must register to access.
Efficacy and Safety of a Targeted-release Formulation of Budesonide (HR19042 Capsules) in Patients With Primary IgA Nephropathy: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2/3 Trial
Open to view video.
Open to view video.
You must register to access.
Evaluating the Effect of Sparsentan vs Irbesartan on Urine Inflammatory and Profibrotic Biomarkers in the Phase 3 Protect Trial of Patients With Immunoglobulin a Nephropathy
Open to view video.
Open to view video.
You must register to access.
Efficacy and Safety of Iptacopan in Patients With IgA Nephropathy (IgAN): Final 24-month Results From the Phase III Applause-IgAN Study
Open to view video.
Open to view video.
You must register to access.
Q&A
Open to view video.
Open to view video.
You must register to access.